Technology Introduction:
This technology platform integrates multi-omics and liquid biopsy data of pancreatic cancer, combined with in silico analysis and patient-derived models, to precisely decode molecular subtypes, immune microenvironment, and drug responses. It has been clinically validated in over 400 patient cases, enabling non-invasive disease monitoring and personalized treatment decision-making, with high potential for clinical translation and commercialization.
Industry Applicability:
This platform integrates cfDNA and EV-based liquid biopsy for tumor monitoring and treatment response, with companion diagnostic potential. Using multi-omics and AI, it builds drug sensitivity and prognosis models for personalized therapy. Gene therapies offer high specificity and low toxicity. Applied in 400+ cases, it expands to other GI cancers and smart medicine, with robust data management and cross-disciplinary collaboration, advancing commercialization and Taiwan’s biotech growth.